Lyudmila A. Bazhenova, MD, discusses the PACIFIC study with durvalumab in stage III non–small-cell lung cancer.
Lyudmila A. Bazhenova, MD
Advertisement
Lyudmila A. Bazhenova, MD, is a clinical professor of medicine at the University of California San Diego (UCSD); as well as a medical oncologist at the UCSD Moores Cancer Center
Articles by Lyudmila A. Bazhenova, MD
Lyudmila A. Bazhenova, MD, discusses the PACIFIC study with durvalumab in stage III non–small-cell lung cancer.
Lyudmila A. Bazhenova, MD, medical oncologist, professor of clinical medicine, University of California, San Diego, discusses new developments in RET-rearranged non–small cell lung cancer.
Lyudmila A. Bazhenova, MD, medical oncologist, professor of clinical medicine, University of California, San Diego, discusses research that has looked at the use of EGFR TKIs after immunotherapy in patients with EGFR-mutant non–small cell lung cancer.
Lyudmila A. Bazhenova, MD, medical oncologist, professor of clinical medicine, University of California, San Diego, discusses sequencing beyond progression on osimertinib (Tagrisso) in EGFR-mutant non–small cell lung cancer (NSCLC).
Lyudmila A. Bazhenova, MD, medical oncologist professor of medicine, University of California, San Diego, discusses the prevalence of NTRK mutations in non–small cell lung cancer.
Advertisement
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
4
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
5